Federal Register / Vol. 74, No. 185 / Friday, September 25, 2009 / Notices 48993 

minority groups, and physically 

challenged individuals are adequately 

represented on the MEDCAC. Therefore, 

we encourage nominations of qualified 

candidates from these groups. 

All nominations must be 

accompanied by curricula vitae. 

Nomination packages must be sent to 

Maria Ellis at the address listed in the 

ADDRESSES section of this notice. 

Nominees for voting membership must 

also have expertise and experience in 

one or more of the following fields: 

• Clinical medicine of all specialties. 

• Administrative medicine. 

• Public health. 

• Patient advocacy. 

• Biologic and physical sciences. 

• Health care data and information 

management and analysis. 

• The economics of health care. 

• Medical ethics. 

• Other related professions such as 

epidemiology and biostatistics, and 

methodology of clinical trial design. 

We are looking for experts in a 

number of fields. Our most critical 

needs are for experts in hematology; 

genomics; end of life care; Bayesian 

statistics; clinical epidemiology; clinical 

trial methodology; knee, hip, and other 

joint replacement surgery; 

ophthalmology; psychopharmacology; 

registries; rheumatology; screening and 

diagnostic testing analysis; and stroke. 

We also need experts in biostatistics in 

clinical settings, cardiovascular 

epidemiology, cost effectiveness 

analysis, dementia, endocrinology, 

geriatrics, gynecology, minority health, 

observational research design, stroke, 

epidemiology, and women’s health. 

The nomination letter must include a 

statement that the nominee is willing to 

serve as a member of the MEDCAC and 

appears to have no conflict of interest 

that would preclude membership. We 

are requesting that all curricula vitae 

include the following: 

• Date of birth. 

• Place of birth. 

• Social security number. 

• Title and current position. 

• Professional affiliation. 

• Home and business address. 

• Telephone and fax numbers. 

• E-mail address. 

• List of areas of expertise. 

In the nominations letter, we are 

requesting that the nominee specify 

whether applying for a Voting position 

or Industry Representative. Potential 

candidates will be asked to provide 

detailed information concerning such 

matters as financial holdings, 

consultancies, and research grants or 

contracts in order to permit evaluation 

of possible sources of conflict of 

interest. 

Members are invited to serve for 

overlapping 2-year terms. A member 

may serve after the expiration of the 

member’s term until a successor takes 

office. Any interested person may 

nominate one or more qualified persons. 

Self-nominations are also accepted. 

The current Secretary’s Charter for the 

MEDCAC is available on the CMS Web 

site at: http://www.cms.hhs.gov/FACA/ 

Downloads/medcaccharter.pdf, or you 

may obtain a copy of the charter by 

submitting a request to the contact listed 

in the FOR FURTHER INFORMATION section 

of this notice. 

Authority: 5 U.S.C. App. 2, section 10(a)(1) 

and (a)(2). 

(Catalog of Federal Domestic Assistance 

Program No. 93.773, Medicare—Hospital 

Insurance; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program) 

Dated: September 21, 2009. 

Barry M. Straube, 

CMS Chief Medical Officer, Director, Office 

of Clinical Standards and Quality, Centers 

for Medicare & Medicaid Services. 

[FR Doc. E9–23257 Filed 9–24–09; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Listing of Members of the 

National Institutes of Health’s Senior 

Executive Service 2009 Performance 

Review Board (PRB) 

The National Institutes of Health 

(NIH) announces the persons who will 

serve on the National Institutes of 

Health’s Senior Executive Service 2009 

Performance Review Board. This action 

is being taken in accordance with Title 

5, U.S.C., Section 4314(c)(4), which 

requires that members of performance 

review boards be appointed in a manner 

to ensure consistency, stability, and 

objectivity in performance appraisals 

and requires that notice of the 

appointment of an individual to serve as 

a member be published in the Federal 

Register. 

The following persons will serve on 

the NIH Performance Review Board, 

which oversees the evaluation of 

performance appraisals of NIH Senior 

Executive Service (SES) members: Ms. 

Colleen Barros (Chair); Dr. Michael 

Gottesman; Ms. Lenora Johnson; Ms. 

Robin Kawazoe; Dr. Raynard Kington; 

Ms. Janis Mullaney; Dr. Sally Rockey. 

For further information about the NIH 

Performance Review Board, contact the 

Office of Human Resources, Workforce 

Relations Division, National Institutes of 

Health, Building 31, Room B3C07, 

Bethesda, Maryland 20892, telephone 

301–402–9203 (not a toll-free number). 

Dated: September 20, 2009. 

Francis S. Collins, 

Director, National Institutes of Health. 

[FR Doc. E9–23265 Filed 9–24–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0026] 

Apothecon et al.; Withdrawal of 

Approval of 103 New Drug 

Applications and 35 Abbreviated New 

Drug Applications; Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; correction. 

SUMMARY: The Food and Drug 

Administration (FDA) is correcting a 

notice that appeared in the Federal 

Register of February 11, 2009 (74 FR 

6896). The document announced the 

withdrawal of approval of 103 new drug 

applications (NDAs) and 35 abbreviated 

new drug applications (ANDAs). The 

document published with an error in 

the identification of the ANDA for 

Amiodarone Hydrochloride Injection, 

50 milligrams/milliliter, held by 

Hospira, Inc. This document corrects 

that error. 

DATES: Effective March 13, 2009. 

FOR FURTHER INFORMATION CONTACT: 

Florine P. Purdie, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 51, rm. 6366, 

Silver Spring, MD 20993–0002, 301– 

796–3601. 

SUPPLEMENTARY INFORMATION: In FR Doc. 

E9–2901, appearing on page 6896 in the 

Federal Register of Wednesday, 

February 11, 2009, the following 

correction is made: 

On page 6900, in the first column of 

the table, third item from the bottom of 

the page, the entry ‘‘ANDA 75–108’’ is 

corrected to read ‘‘ANDA 76–108’’. 

Dated: September 9, 2009. 

Douglas C. Throckmorton, 

Deputy Director, Center for Drug Evaluation 

and Research. 

[FR Doc. E9–23170 Filed 9–24–09; 8:45 am] 

BILLING CODE 4160–01–S 


jlentini on DSKJ8SOYB1PROD with NOTICES